Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length
- PMID: 32109421
- PMCID: PMC7058826
- DOI: 10.1016/j.ajhg.2020.02.006
Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length
Abstract
Leukocyte telomere length (LTL) is a heritable biomarker of genomic aging. In this study, we perform a genome-wide meta-analysis of LTL by pooling densely genotyped and imputed association results across large-scale European-descent studies including up to 78,592 individuals. We identify 49 genomic regions at a false dicovery rate (FDR) < 0.05 threshold and prioritize genes at 31, with five highlighting nucleotide metabolism as an important regulator of LTL. We report six genome-wide significant loci in or near SENP7, MOB1B, CARMIL1, PRRC2A, TERF2, and RFWD3, and our results support recently identified PARP1, POT1, ATM, and MPHOSPH6 loci. Phenome-wide analyses in >350,000 UK Biobank participants suggest that genetically shorter telomere length increases the risk of hypothyroidism and decreases the risk of thyroid cancer, lymphoma, and a range of proliferative conditions. Our results replicate previously reported associations with increased risk of coronary artery disease and lower risk for multiple cancer types. Our findings substantially expand current knowledge on genes that regulate LTL and their impact on human health and disease.
Keywords: Mendelian randomisation; age-related disease; biological aging; telomere length.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
A.S.B. holds grants unrelated to this work from AstraZeneca, Merck, Novartis, Biogen, and Bioverativ/Sanofi.
J.D. reports personal fees and non-financial support from Merck Sharpe and Dohme UK Atherosclerosis; personal fees and non-financial support from Novartis Cardiovascular and Metabolic Advisory Board; personal fees and non-financial support from Pfizer Population Research Advisory Panel; and grants from the British Heart Foundation, the European Research Council, Merck, the NIHR, NHS Blood and Transplant, Novartis, Pfizer, the UK Medical Research Council, Health Data Research UK, and the Wellcome Trust outside the submitted work.
Figures
References
-
- de Lange T. Shelterin-Mediated Telomere Protection. Annu. Rev. Genet. 2018;52:223–247. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MR/L003120/1/MRC_/Medical Research Council/United Kingdom
- 29017/CRUK_/Cancer Research UK/United Kingdom
- RG/18/13/33946/BHF_/British Heart Foundation/United Kingdom
- RG/13/13/30194/BHF_/British Heart Foundation/United Kingdom
- MC_UU_12015/1/MRC_/Medical Research Council/United Kingdom
- MC_UU_12015/2/MRC_/Medical Research Council/United Kingdom
- 19170/CRUK_/Cancer Research UK/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- MC_UU_00006/2/MRC_/Medical Research Council/United Kingdom
- 001/WHO_/World Health Organization/International
- MR/S019669/1/MRC_/Medical Research Council/United Kingdom
